Whitehouse Scientific’s managing director, Jamie Storey, showed his support for ‘Movember’ by joining more than 850,000 fellow ‘Mo Bros’ from around the world in growing facial hair throughout the month of November.
From humble beginnings, ‘Movember’ has become a global campaign aimed at raising vital funds and awareness for men’s health, specifically prostate and testicular cancer. It is one of a number of charity initiatives supported by the Whitehouse Scientific team.
‘Although I have spent the month looking a bit of a fool it was worth it for such a great cause,’ said Storey.
‘With awareness being the key, it was a pleasure explaining why I had grown a handlebar moustache to the many who have asked. I look forward to trying out a new style next year.’
Funds raised by ‘Movember’ in the UK are directed to The Prostate Cancer Charity and Institute of Cancer Research, which supports programmes aimed at increasing early cancer detection, diagnosis and effective treatments, and ultimately reducing the number of preventable deaths.
To date, ‘Movember’ has raised nearly £65m, with £15m coming from the UK. A total of £170m has been collected since 2004.
Whitehouse md grows moustache for charity
Joins fellow ‘Mo Bros’ around the world to raise funds and awareness for men’s health
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist